Superworth

Cerus revenue CERS

Sales by quarter and over the last twelve months, from 2010.

Last 12 months, to Sep 30, 2026
$233.4M
Latest quarter, Q3 FY26
$57.7M
+10% on a year earlier
Fiscal year 2025
$213M
+6% on the year before

Cerus' revenue was $233.4M over the twelve months to Sep 30, 2026, up 14% on a year earlier.

In its latest quarter, Q3 FY26, it was $57.7M, up 10% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 13% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$213M+6%
FY2024$201.3M+8%
FY2023$186.8M−1%
FY2022$188.3M+18%
FY2021$159.5M+40%
FY2020$114.2M+22%
FY2019$93.8M+23%
FY2018$76.1M+75%
FY2017$43.6M+17%
FY2016$37.2M+9%
FY2015$34.2M−6%
FY2014$36.4M−8%
FY2013$39.7M+8%
FY2012$36.7M+20%
FY2011$30.6Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY26$57.7M+10%$233.4M
Q2 FY26$57.4M+10%$228.4M
Q1 FY26$53.7M+24%$223.4M
Q4 FY25$64.6M+14%$213M
Q3 FY25$52.7M+4%$205.1M
Q2 FY25$52.4M+4%$203.1M
Q1 FY25$43.2M−0%$201.2M
Q4 FY24$56.8M+6%$201.3M
Q3 FY24$50.7M+7%$197.9M
Q2 FY24$50.5M+6%$194.5M
Q1 FY24$43.4M+13%$191.7M
Q4 FY23$53.3M+4%$186.8M

Against its peers

Companies in Medical - Instruments & Supplies nearest Cerus' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
CERSCerus$235.9M+14% a year
TCMDTactile Systems Technology$350.3M+17% a year
EMBCEmbecta$1B−8% a year
MOVMovado$689.9M+5% a year
INFUInfuSystem$143.3M+2% a year
UTMDUtah Medical Products$36.1M−7% a year
IRMDIradimed$89.3M+11% a year
IARTIntegra Lifesciences$1.7B+1% a year
BVSBioventus$581.8M+4% a year
PDEXPro DEX$79.6M+13% a year
STAAStaar Surgical$339.6M+51% a year
Peer median$345M

Where Cerus ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Cerus

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.